Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate

BACKGROUND: We and others have identified the aldo-keto reductase AKR1C3 as a potential drug target in prostate cancer, breast cancer and leukaemia. As a consequence, significant effort is being invested in the development of AKR1C3-selective inhibitors. METHODS: We report the screening of an in-hou...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanim, F, Davies, N, Veliça, P, Hayden, R, Ride, J, Pararasa, C, Chong, M G, Gunther, U, Veerapen, N, Winn, P, Farmer, R, Trivier, E, Rigoreau, L, Drayson, M, Bunce, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960632/
https://www.ncbi.nlm.nih.gov/pubmed/24569460
http://dx.doi.org/10.1038/bjc.2014.83

Ejemplares similares

Ejemplares similares